Cite

HARVARD Citation

    Mozessohn, L. et al. (2020). Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the 'real-world'. Leukemia & lymphoma. 61 (6), pp. 1445-1454. [Online]. 
  
Back to record